NCT 10015
Alternative Names: NCT10015Latest Information Update: 28 Mar 2023
At a glance
- Originator NeuroCycle Therapeutics
- Developer Engrail Therapeutics
- Class Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dravet syndrome
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Dravet-syndrome in USA
- 02 Feb 2021 NeuroCycle Therapeutics has been acquired and merged into Engrail Therapeutics
- 13 Feb 2019 NeuroCycle Therapeutics receives SBIR grant from National institute of Neurological Disorders and Stroke for NCT 10015 development in Dravet syndrome